Home › Research › Treatments
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M et al.. Alzheimer's research & therapy, 2024-05-10
Topic: Amyloid, tau and blood-test diagnosis
Results Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included.
Key findings
- Results Overall, 1795 participants from Core and 1612 participants with at least one dose of lecanemab (Core + OLE) were included.
Why it matters
This report gives updated safety results from a phase 3 lecanemab study in early Alzheimer's disease, covering 1795 participants in the core study and 1612 who received at least one dose. It is about safety data and does not report on whether the drug cures or prevents the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designopen-label trial
- Participants1,795
- Effect size24.5%; 16.0%; 14.7%
- Evidence strengthHigh
How this study scored 78/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,795 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 174 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 43.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 6 / 6 | Cited 41.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 25 other studies in this library |
| Still being cited | 3 / 4 | Cited 173 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Lynn Darden Kramer: h-index 27 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38730496) |
| Free to read | 2 / 2 | Free to read |
| Total | 78 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-024-01441-8
- PubMed: 38730496
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Honig, L. S., Sabbagh, M. N., van Dyck, C. H., Sperling, R. A., Hersch, S., Matta, A., et al. (2024). Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-024-01441-8
Vancouver
Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. Alzheimer's research & therapy. 2024. doi:10.1186/s13195-024-01441-8. PMID: 38730496.
BibTeX
@article{honig2024-38730496,
author = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others},
title = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}},
journal = {Alzheimer's research \& therapy},
year = {2024},
doi = {10.1186/s13195-024-01441-8},
pmid = {38730496},
url = {https://doi.org/10.1186/s13195-024-01441-8}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.